- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Recent Approvals, Collaborative Care Model Spark Change in HCC Treatment
March 2nd 2020, 11:38pm
Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.
Dr. Salem on Locoregional Therapy Versus Systemic Therapy in HCC
March 2nd 2020, 9:34pm
Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.
Dr. Singal on the Importance of Early Diagnosis in HCC
March 2nd 2020, 9:30pm
Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.
Pivotal Studies Provide New Path in High-Risk Smoldering Myeloma
March 2nd 2020, 6:18am
PER® Congress on Hematologic Malignancies (Winter Hematology®)
The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.
Immunotherapy Combinations Show Promise in Advanced HCC
March 2nd 2020, 1:38am
Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.
Evidence Illustrates Multidisciplinary Care Is Standard in HCC
March 1st 2020, 9:29pm
Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.
Pillai Reflects on Achieved Goals at Inaugural HCC-TAG Conference
March 1st 2020, 8:53pm
Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm
Next Chapter Begins With CAR T-Cell Therapy in Myeloma
March 1st 2020, 8:39pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.
Unmet Needs Remain in GVHD, But Novel Approaches on Horizon
March 1st 2020, 8:34pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.
Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies
March 1st 2020, 7:51pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.
Dr. Hoshida on Molecular Subtyping in HCC
March 1st 2020, 4:33am
Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.
Dr. Pinato on Biomarker Challenges in HCC
March 1st 2020, 4:30am
David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.
Burst of Targeted Agents Leads to Transformed HCC Paradigm
February 29th 2020, 11:12pm
Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.
Deep Data Dive Needed for Upfront Treatment Selection in iNHL
February 29th 2020, 10:58pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.
Biomarker Hunt Gains Traction Among Therapeutic Advances in HCC
February 29th 2020, 10:45pm
David J. Pinato, MD, PhD, highlights the clinical and biological challenges in identifying biomarkers in hepatocellular carcinoma, and the potential introduction of biomarkers in the future.
Acalabrutinib Approval Leads Frontline Advances in CLL
February 29th 2020, 10:39pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
A number of therapeutic options have become available in the frontline setting for patients with chronic lymphocytic leukemia, most recently the second-generation BTK inhibitor acalabrutinib.
Dr. Smith on the Guiding Principles for Treating iNHL
February 29th 2020, 8:43pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
Sonali M. Smith, MD, discusses the prognosis of patients with indolent non-Hodgkin lymphomas.
Key AE Management Strategies in Place for CAR T-Cell Therapy in Hematologic Cancers
February 29th 2020, 7:55pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.
Dr. Cortes on Tyrosine Kinase Inhibitors in CML
February 29th 2020, 7:03am
PER® Congress on Hematologic Malignancies (Winter Hematology®)
Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.
Dr. Parikh on the Importance of Multidisciplinary Care in HCC
February 29th 2020, 6:14am
Neehar Parikh, MD, discusses the importance of multidisciplinary care in the treatment of patients with hepatocellular carcinoma.